VivoSeq
Oncology

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified

3

Pipeline Programs↗

1

Active Trials↗

2

Companies Involved↗

Diffuse Large B-Cell Lymphoma, Not Otherwise Specified is an early-stage landscape with 3 programs across 2 companies. The most active players are Roche, Karuna Therapeutics, Inc., a Bristol Myers Squibb company.

Intelligence

Pipeline Metrics

Competitive Density

22/100

Pipeline Velocity

0/100

Mech. Concentration

33/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

2 programs

Phase 1K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Mosunetuzumab

Roche

Polatuzumab Vedotin

Roche

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

3programs
Small molecule133%
Monoclonal antibody133%
Antibody–drug conjugate133%

Modality classified for 100% of 3 pipeline programs.

Analysis

Trial Status

1

clinical trials

Recruiting1 · 100%

Clinical Trials

Trial Activity

A Phase 1 Study of Mosunetuzumab With Polatuzumab Vedotin and Lenalidomide (M+Pola+Len) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
Recruiting·National Cancer Institute (NCI)·Phase 1·NCT06015880·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)